Literature DB >> 15517127

[New therapeutic approaches to COPD].

M Pfeifer1.   

Abstract

Classification of severity of the disease is the basis of the therapeutic concept for chronic obstructive lung disease (COPD). Besides pharmacological treatment, preventive measures and rehabilitation with training are the main parts of COPD therapy. Weaning patients of cigarette smoking is of utmost importance in every stage for the course of the disease. Inhalative short acting bronchodilators on demand are the basis of treatment in all stages as well as long acting bronchodilators from stage II on as continuous medication. Theophyllines are of additional importance in higher degrees of the disease. Inhalative steroids are indicated in severe stages III or higher, systemic steroids only during exacerbations as short course therapy. Oxygen long time treatment, intermittent non-invasive ventilation, and operations in some cases are additional therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517127     DOI: 10.1007/s00108-004-1293-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  40 in total

Review 1.  Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Bronchoscopic volume reduction with valve implants in patients with severe emphysema.

Authors:  Tudor P Toma; Nicholas S Hopkinson; James Hillier; David M Hansell; Clifford Morgan; Peter G Goldstraw; Michael I Polkey; Duncan M Geddes
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

3.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

4.  A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease.

Authors:  R H Green; S J Singh; J Williams; M D Morgan
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

Review 5.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

6.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

Authors:  Robert Wise; John Connett; Gail Weinmann; Paul Scanlon; Melissa Skeans
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

7.  Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease.

Authors:  D D Sin; J V Tu
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

8.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.

Authors:  R Dahl; L A Greefhorst; D Nowak; V Nonikov; A M Byrne; M H Thomson; D Till; G Della Cioppa
Journal:  Am J Respir Crit Care Med       Date:  2001-09-01       Impact factor: 21.405

9.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.

Authors:  W Vincken; J A van Noord; A P M Greefhorst; Th A Bantje; S Kesten; L Korducki; P J G Cornelissen
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

10.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.

Authors:  W Szafranski; A Cukier; A Ramirez; G Menga; R Sansores; S Nahabedian; S Peterson; H Olsson
Journal:  Eur Respir J       Date:  2003-01       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.